Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Earl Giller

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
GanaxoloneVirinder Nohria, Earl Giller
International Clinical Psychopharmacology|December 1, 2005
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophreniaJohn M Kane, Sumant Khanna, Sunita Rajadhyaksha, et al.
The American Journal of Psychiatry|April 2, 2003
Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trialPaul E Keck, Marcio Versiani, Steven Potkin, et al.
Epilepsia|July 20, 2007
Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsyVincent A Pieribone, Julia Tsai, Christine Soufflet, et al.
The Journal of Clinical Psychiatry|October 6, 2007
Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation studyAntony D Loebel, Sumant Khanna, Sunita Rajadhyaksha, et al.
Schizophrenia Research|March 27, 2009
Weight effects associated with antipsychotics: a comprehensive database analysisBruce Parsons, David B Allison, Antony Loebel, et al.
Journal of Clinical Psychopharmacology|October 22, 2015
Comparison of Site-Based Versus Central Ratings in a Study of Generalized Anxiety DisorderJanet B W Williams, Kenneth A Kobak, Earl Giller, et al.
Journal of Psychiatric Research|March 12, 2014
A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophreniaJoan H Q Shen, Yonggang Zhao, Sharon Rosenzweig-Lipson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 3, 2007
GanaxoloneVirinder Nohria, Earl Giller
International Clinical Psychopharmacology|December 1, 2005
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophreniaJohn M Kane, Sumant Khanna, Sunita Rajadhyaksha, et al.
The American Journal of Psychiatry|April 2, 2003
Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trialPaul E Keck, Marcio Versiani, Steven Potkin, et al.
Epilepsia|July 20, 2007
Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsyVincent A Pieribone, Julia Tsai, Christine Soufflet, et al.
The Journal of Clinical Psychiatry|October 6, 2007
Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation studyAntony D Loebel, Sumant Khanna, Sunita Rajadhyaksha, et al.
Schizophrenia Research|March 27, 2009
Weight effects associated with antipsychotics: a comprehensive database analysisBruce Parsons, David B Allison, Antony Loebel, et al.
Journal of Clinical Psychopharmacology|October 22, 2015
Comparison of Site-Based Versus Central Ratings in a Study of Generalized Anxiety DisorderJanet B W Williams, Kenneth A Kobak, Earl Giller, et al.
Journal of Psychiatric Research|March 12, 2014
A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophreniaJoan H Q Shen, Yonggang Zhao, Sharon Rosenzweig-Lipson, et al.
Pageof 1